Related references
Note: Only part of the references are listed.Preventing the calorie restriction-induced increase in insulin-stimulated Akt2 phosphorylation eliminates calorie restriction's effect on glucose uptake in skeletal muscle
Naveen Sharma et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2012)
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2012)
The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas
Dakeun Lee et al.
MODERN PATHOLOGY (2012)
Phase 1/2 Study of Everolimus in Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
CANCER (2011)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Nonredundant Functions for Akt Isoforms in Astrocyte Growth and Gliomagenesis in an Orthotopic Transplantation Model
Raelene Endersby et al.
CANCER RESEARCH (2011)
Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells
Nicole Grabinski et al.
CELLULAR SIGNALLING (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Vanessa S. Rodrik-Outmezguine et al.
CANCER DISCOVERY (2011)
mTOR phosphorylated at S2448 binds to raptor and rictor
M. Rosner et al.
AMINO ACIDS (2010)
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Ryan J. O. Dowling et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo
Craig Cherrin et al.
CANCER BIOLOGY & THERAPY (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Akt inhibitors in clinical development for the treatment of cancer
Sumanta Kumar Pal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Akt kinases Isoform specificity in metabolism and cancer
Eva Gonzalez et al.
CELL CYCLE (2009)
The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma
Joon-Yong Chung et al.
CLINICAL CANCER RESEARCH (2009)
Targeting the mTOR Signaling Network for Cancer Therapy
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
Xuerong Wang et al.
CANCER RESEARCH (2008)
Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer
Magnus Rizell et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2008)
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
Michael Degtyarev et al.
JOURNAL OF CELL BIOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
AKT and ERK1/2 signaling in intrahepatic cholanglocarcinoma
K. J. Schmitz et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Timeline - Insights from transgenic mouse models of ERBB2-induced breast cancer
Josie Ursini-Siegel et al.
NATURE REVIEWS CANCER (2007)
AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines
Sandra Koseoglu et al.
CANCER BIOLOGY & THERAPY (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding
Lisa Heron-Milhavet et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States
Tania M. Welzel et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Akt signaling and cancer: Surviving but not moving on
A Toker et al.
CANCER RESEARCH (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade
YJ Shi et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Surgical management of cholangiocarcinoma
WR Jarnagin et al.
SEMINARS IN LIVER DISEASE (2004)
PI3K/Akt signalling pathway and cancer
JAF Vara et al.
CANCER TREATMENT REVIEWS (2004)
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma
WR Jarnagin et al.
ANNALS OF SURGERY (2001)
Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene
WS Chen et al.
GENES & DEVELOPMENT (2001)
Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ)
H Cho et al.
SCIENCE (2001)
Share Paper
